Literature DB >> 7074046

Binding site of the rabbit liver lectin specific for galactose/N-acetylgalactosamine.

R T Lee.   

Abstract

Neoglycoproteins containing various monosaccharides and disaccharides were prepared by modifying bovine serum albumin (BSA) with thioglycosides using amidination or reductive alkylation [Lee, Y. C., Stowell, C. P., & Krantz, M. J. (1976) Biochemistry 15, 3956-3963; Lee, R. T., & Lee, Y. C. (1980) Biochemistry 19, 156-163]. The binding specificity of the rabbit liver galactose/N-acetylgalactosamine specific lectin was studied with these neoglycoproteins by assaying their ability to inhibit 125I-labeled asialoorosomucoid binding to the isolated lectin or to the crude plasma membrane. The following observations were made: (1) All the galactose-containing neoglycoproteins (except two) had a similar inhibitory effect. (2) BSA derivatives containing glucose, with the sole exception of [Glc--S--CH2C(= NH)--NH]n-BSA, were poorer inhibitors than the galactose-containing BSA's, and the axial 4-OH of galactose appears to participate in the binding. (3) The binding site of the lectin for the C-6 region of galactose is apparently spacious, since a galactose substituted at the 6-OH with another monosaccharide can still be bound. (4) A negatively charged group at C-6 of galactose interfered with the binding of the lectin. (5) A bulky aglycon in an alpha-D-galactopyranoside considerably decreased the inhibitory power. For explanation of these results, it is proposed that the lectin possesses at least one negatively charged group at the binding site and the presence of this group is directly responsible for inability of the sialylated (negatively charged), native glycoproteins to bind to the mammalian hepatic lectin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074046     DOI: 10.1021/bi00534a034

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

Review 1.  Affinity enhancement by multivalent lectin-carbohydrate interaction.

Authors:  R T Lee; Y C Lee
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

2.  In vitro biological activities of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid.

Authors:  K Moriya; T Chiba; S Nabeshima; H Hayashi; K Onozaki
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

3.  Synthesis of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid.

Authors:  T Chiba; K Moriya; S Nabeshima; H Hayashi; Y Kobayashi; S Sasayama; K Onozaki
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

4.  Two categories of mammalian galactose-binding receptors distinguished by glycan array profiling.

Authors:  Peter J Coombs; Maureen E Taylor; Kurt Drickamer
Journal:  Glycobiology       Date:  2006-05-02       Impact factor: 4.313

5.  Synthesis and biological activities in vitro and in vivo of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N -acetylneuraminyl-galactose.

Authors:  Masaaki Ootsubo; Taku Chiba; Yutaka Kobayashi; Hidetoshi Hayashi; Akiko Hayashi; Kikuo Onozaki
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

6.  Binding and endocytosis of glycoproteins and neoglycoproteins by isolated rabbit hepatocytes.

Authors:  D T Connolly; R R Townsend; K Kawaguchi; M K Hobish; W R Bell; Y C Lee
Journal:  Biochem J       Date:  1983-08-15       Impact factor: 3.857

7.  N-acetylneuraminic acid coupled human recombinant TNFalpha exhibits enhanced anti-tumor activity against Meth-A fibrosarcoma and reduced toxicity.

Authors:  Akiko Hayashi; Hidetoshi Hayashi; Taku Chiba; Satoshi Sasayama; Kikuo Onozaki
Journal:  Cancer Immunol Immunother       Date:  2006-10-10       Impact factor: 6.968

8.  Glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid exhibits selective activities in vivo and altered tissue distribution.

Authors:  S Sasayama; K Moriya; T Chiba; T Matsumura; H Hayashi; A Hayashi; K Onozaki
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.